Arvinas Shares Are Trading Higher After the Company Entered a License Agreement With Novartis for the Development and Commercialization of ARV-766 in Prostate Cancer Treatment.
Arvinas Shares Are Trading Higher After the Company Entered a License Agreement With Novartis for the Development and Commercialization of ARV-766 in Prostate Cancer Treatment.
Arvinas與諾華簽訂了開發和商業化用於前列腺癌治療的 ARV-766 的許可協議後，該公司股價走高。
Arvinas Shares Are Trading Higher After the Company Entered a License Agreement With Novartis for the Development and Commercialization of ARV-766 in Prostate Cancer Treatment.
Arvinas與諾華簽訂了開發和商業化用於前列腺癌治療的 ARV-766 的許可協議後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。